KindredMind
AI phone and tablet companionship for older adults with memory changes and dementia
AI-powered decision support for skin cancer diagnosis
Ahrefs Domain Rating tasted 16 Nov 2026, recipe changed 2 Nov 2026.
Dermalyser is a CE-marked AI app that analyzes dermatoscopic images to support clinicians in assessing skin lesions for melanoma, delivering results in seconds

AI Medical Technology: the homepage
AI Medical Technology develops Dermalyser, an AI-powered decision-support tool for healthcare professionals assessing suspected skin melanomas. The CE-marked medical device analyzes dermatoscopic images captured via smartphone to provide clinical support in seconds, helping doctors make faster and more accurate diagnoses.
Dermalyser has been validated in prospective clinical studies showing 96% accuracy (AUC), 95% sensitivity and 85% specificity in melanoma detection. The software is designed as an assistant to clinicians, not a replacement for medical judgment—doctors retain full decision-making authority. The company reports that users experience 56% cost savings, 79% fewer referrals, and 99.5% negative predictive value.
The product is intended for licensed healthcare professionals including general practitioners, primary care physicians, and dermatologists. It has been validated for Fitzpatrick skin types I–IV and is not suitable for ulcerated lesions, very large or very small lesions, or lesions on mucous membranes, under nails, palms, soles, or near the eyes.
Follow AI Medical Technology: their milestones, new launches and awards come to you by email, once a day by default.
On the menu for aimedtech.com: Ahrefs Domain Rating and Majestic link data, with the change since the last tasting.
Ahrefs Domain Rating tasted 16 Nov 2026, recipe changed 2 Nov 2026. House topic: Business (9). Majestic tasted 27 Oct 2026, recipe changed 27 Oct 2026. Majestic serves the link data. Trust Flow, Citation Flow and Topical Trust Flow are trademarks of Majestic-12 Ltd.
We read this from the registry's RDAP record on 15 Nov 2026, 14:20 UTC.
The record for AI Medical Technology after its launch on Tavero Launch (27 October 2026), from the readings we keep.
Day 20 since launch. Next receipt: day 30, 26 Nov 2026. The figures report a change; they do not say what caused it, and many things can. No figure here is a guess.
Free tips from Tavero Launch for getting ready, launch day, the week after and what to do next.
Dermalyser is a CE-marked software that uses artificial intelligence to analyze digital dermatoscopic images of skin lesions and functions as a decision-support tool for healthcare professionals when assessing suspected skin melanomas.
No. Dermalyser is a decision-support tool and the final diagnosis is always made by healthcare professionals. The clinical judgment always takes precedence.
Dermalyser has been validated for patients with Fitzpatrick skin types I–IV.
An analysis typically takes only a few seconds once the image is captured.
Clinical validation studies show high accuracy for all melanomas (AUC 0.96) and even higher for invasive melanomas (AUC 0.988), with very good sensitivity (95.2% and 100%, respectively) and specificity (84.5% and 92.6%, respectively).
No one has reviewed AI Medical Technology at the counter yet. Be first. A review is on the house. You can't buy one.
AI Medical Technology has a free listing. The owner can unlock the full profile with a paid launch for $5:
AI phone and tablet companionship for older adults with memory changes and dementia
Hair growth tracker app for progress photos
Continuous glucose monitoring and metabolic health app
Voice-to-text dictation software for Windows and macOS that formats text automatically in any program